Core Insights - Chongqing Boteng Pharmaceutical Technology Co., Ltd. reported a revenue of 1.621 billion yuan for the first half of 2025, marking a year-on-year increase of 19.88%, and a net profit attributable to shareholders of 27.06 million yuan, indicating a turnaround from losses [1] - The company focused on enhancing its core business capabilities in marketing, R&D, and integrated delivery, targeting high-value markets and projects, achieving its key operational goals of revenue recovery and profit turnaround [1] Revenue Breakdown - Revenue growth in the first half of the year was driven by the small molecule API business, gene cell therapy, and new molecular business segments, with small molecule API revenue increasing by approximately 20%, gene cell therapy by about 71%, and new molecular business by around 128% [2] - The small molecule formulation business saw a revenue decline of 7% year-on-year, primarily due to market demand fluctuations caused by centralized procurement policies [2] - Revenue growth was mainly from the European and North American markets, with Europe growing by approximately 35% and North America by about 33%; the U.S. subsidiary J-STAR achieved revenue of 181 million yuan, a year-on-year increase of about 48% [2] Global Operations and R&D - As of the reporting period, the company operates 18 facilities in China, the U.S., and Europe, providing customized R&D and production services across various drug types [3] - The company employs 1,244 R&D personnel across its teams in the U.S. (133), Europe (31), and China (1,080), focusing on faster innovation and resource concentration to maintain core competitiveness [3] - The company has established a global operational footprint to meet diverse project service needs from early development to commercial production, ensuring cost efficiency and supply chain security for clients [3]